112,771 Shares in Glaukos Co. (NYSE:GKOS) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new position in Glaukos Co. (NYSE:GKOS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 112,771 shares of the medical instruments supplier’s stock, valued at approximately $16,910,000.

Several other large investors have also made changes to their positions in the company. Mutual of America Capital Management LLC raised its position in shares of Glaukos by 1.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock worth $1,252,000 after buying an additional 89 shares during the period. Louisiana State Employees Retirement System raised its position in Glaukos by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock valued at $4,003,000 after purchasing an additional 100 shares during the period. Handelsbanken Fonder AB raised its position in Glaukos by 0.7% in the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier’s stock valued at $2,204,000 after purchasing an additional 100 shares during the period. HighTower Advisors LLC raised its position in Glaukos by 3.3% in the third quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier’s stock valued at $416,000 after purchasing an additional 103 shares during the period. Finally, KBC Group NV raised its position in Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Price Performance

GKOS opened at $103.12 on Tuesday. The stock has a fifty day moving average of $139.82 and a 200-day moving average of $137.49. The firm has a market capitalization of $5.83 billion, a P/E ratio of -35.93 and a beta of 0.99. Glaukos Co. has a 12-month low of $85.04 and a 12-month high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The business had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Equities analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Activity

In other news, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,744 shares of company stock worth $2,504,131 over the last quarter. Corporate insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

GKOS has been the topic of several research reports. Wells Fargo & Company raised their price objective on Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Stifel Nicolaus raised their price objective on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, December 31st. UBS Group started coverage on Glaukos in a research report on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective on the stock. Stephens raised Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Needham & Company LLC lifted their target price on Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $163.25.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.